Dimerix (DXB) Investor presentation summary

Strategic focus and pipeline overview

• Focused on developing innovative therapies for kidney diseases with high unmet clinical needs, leveraging expertise in renal disease and small molecule drug development.

• Two main assets: DMX-200 for focal segmental glomerulosclerosis (FSGS) and DMX-652 for acute kidney injury (AKI) associated with cardiac surgery.

• Both assets have differentiated mechanisms of action and are supported by robust intellectual property portfolios and regulatory exclusivity.

DMX-200: FSGS program highlights

• DMX-200 is a CCR2 inhibitor, showing positive safety and efficacy signals in Phase 2 and ongoing Phase 3 trials for FSGS.

• Phase 3 ACTION3 trial fully recruited with >90% statistical power to demonstrate efficacy on proteinuria, a key surrogate endpoint.

• Five commercial licensing partners across major global markets, with deals valued up to AU$1.9 billion in upfront, milestone payments, and royalties.

• Orphan drug designations provide regulatory, marketing exclusivity, and pricing benefits in key territories.

• DMX-200 has a strong safety profile, with no significant safety concerns in over 400 patients dosed.

DMX-652: AKI program highlights

• DMX-652 is a first-in-class USP30 inhibitor targeting mitophagy, with Phase 1 completed and Phase 2 ready to commence.

• Demonstrated strong safety and pharmacokinetic profile in healthy volunteers, with no serious adverse events.

• Addresses a significant unmet need in cardiac surgery-associated AKI, a market estimated at US$3.5 billion in 2026 and US$7.5 billion by 2036.

• Unique mechanism enables removal of damaged mitochondria, aiming to reduce AKI incidence, severity, and progression to chronic kidney disease.

• Broad expansion potential for other indications beyond CS-AKI, supported by robust IP and regulatory exclusivity.